The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Prognostic value of pre-treatment health-related QoL indicators in AML: analysis from EORTC AML21
Fabio Efficace, PhD, Italian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health Outcomes Research Unit, Rome, Italy, comments on the prognostic value of baseline quality of life (QoL) data in patients with acute myeloid leukemia (AML) enrolled in the EORTC AML21 trial (NCT02172872). Dr Efficace notes that this finding has key implications for defining fitness in patients with AML, which is crucial in determining whether a patient can tolerate aggressive treatment. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yeah, in this study we basically analyzed baseline quadruplet data for their prognostic value for overall survival in a patient with AML. And we actually found that quadruplet data provide independent prognostic information for overall survival beyond well-established prognostic factors in this disease. And the key implication is actually that of the definition of fitness, because in a patient with AML, it’s important to evaluate fitness...
Yeah, in this study we basically analyzed baseline quadruplet data for their prognostic value for overall survival in a patient with AML. And we actually found that quadruplet data provide independent prognostic information for overall survival beyond well-established prognostic factors in this disease. And the key implication is actually that of the definition of fitness, because in a patient with AML, it’s important to evaluate fitness. So because based on fitness, you decide whether this patient can cope with aggressive treatment or not. So the fact of having found quadruplet data being a prognostic factor for overall survival actually laid the groundwork for possibly developing a patient-centric metric for evaluating fitness in AML patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
